摘要
新辅助化疗主要应用于局部晚期乳腺癌的治疗,疗效评价常用的指标为临床上缓解和病理学上缓解的程度.Ki-67是与细胞分裂增殖有关的核蛋白,已广泛应用于各种肿瘤的诊断及预后.多项临床研究资料表明Ki-67在判断乳腺癌新辅助化疗是否有效中显示出潜在的价值,现就Ki-67在乳腺癌新辅助化疗中的作用及临床意义作一综述.
Neoadjuvant chemotherapy （NAC）is one of the main strategies for patients with locally ad- vanced breast cancer. Clinical and pathologic response rates are equivalent used for evaluating therapeutic effect. The expression of Ki - 67 protein is associated with cell proliferation. It has been widely used in the diagnosis and prognosis of various tumors. A number of clinical data indicate that Ki -67 demonstrated a potential value in de- termining the effectiveness of neoadjuvant chemotherapy for breast cancer. The role of Ki - 67 on neoadjurant chemotherapy and its clinical significance is reviewed.
出处
《实用肿瘤学杂志》
CAS
2012年第2期188-191,共4页
Practical Oncology Journal
关键词
KI-67
乳腺癌
新辅助化疗
Ki - 67
Breast cancer
Neoadjuvant chemotherapy
